Clene Inc. (CLNN)
| Market Cap | 68.90M |
| Revenue (ttm) | 200,000 |
| Net Income (ttm) | -26.17M |
| Shares Out | 11.78M |
| EPS (ttm) | -2.65 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 26,267 |
| Open | 6.04 |
| Previous Close | 6.06 |
| Day's Range | 5.85 - 6.21 |
| 52-Week Range | 2.28 - 13.50 |
| Beta | 0.62 |
| Analysts | Strong Buy |
| Price Target | 33.00 (+464.1%) |
| Earnings Date | May 8, 2026 |
About CLNN
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company’s lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinde... [Read more]
Financial Performance
In 2025, Clene's revenue was $200,000, a decrease of -41.52% compared to the previous year's $342,000. Losses were -$26.17 million, -33.57% less than in 2024.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for CLNN stock is "Strong Buy." The 12-month stock price target is $33.0, which is an increase of 464.10% from the latest price.
News
Clene Reports Full Year 2025 Financial Results and Recent Operating Highlights
In-person Type C FDA meeting scheduled by end of the first quarter of 2026 to discuss the latest CNM-Au8® data submitted; Clene expects formal written meeting minutes early in the second quarter 2026 ...
Clene Transcript: Emerging Growth Virtual Conference
The company presented compelling clinical data for CNM-Au8 in ALS, showing significant biomarker and survival benefits, and is preparing for a key FDA meeting by end of Q1. NDA filing is targeted for Q2, with commercialization possible in early 2027, supported by recent financing.
Clene Issues Stockholder Letter Highlighting Upcoming CNM-Au8® 2026 Catalysts
SALT LAKE CITY, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene” or the “Company”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-...
Clene to Present at the Emerging Growth Conference
SALT LAKE CITY, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmace...
Clene Transcript: Emerging Growth Conference 89
A pivotal FDA meeting this quarter will review biomarker and survival data supporting accelerated approval for an ALS therapy, with NDA filing targeted for Q2 and possible commercialization early next year. Recent financing extends runway, backed by major healthcare investors.
Clene Announces Additional CNM-Au8 Biomarker Data Supporting Potential NDA Filing for Upcoming In-Person FDA Meeting
SALT LAKE CITY, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene” or the “Company”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a late cli...
Clene Announces Registered Direct Offering of Over $28 Million
Oversubscribed registered direct offering priced above market to new, existing and insider investors, including Boxer Capital Management, Coastlands Capital, and Vivo Capital Initial financing tranche...
Clene Transcript: Emerging Growth Conference 88
Clene is advancing its lead ALS therapy, CNM-Au8, toward accelerated FDA approval using biomarker data, with a New Drug Application planned for the first half of the year. If successful, commercialization could occur by late 2026 or early 2027, addressing a major unmet need.
Clene Transcript: Study Update
Significant reductions in neurofilament and GFAP biomarkers with CNM-Au8 correlated with improved survival in ALS, especially in advanced and bulbar onset patients. The FDA is considering these biomarkers as surrogate endpoints for accelerated approval, and a Phase 3 trial with survival as the primary endpoint is planned.
Clene Announces Statistically Significant ALS Biomarker Results Supporting Accelerated Approval Pathway for CNM-Au8®
FDA recommended biomarker analyses show statistically significant reductions in NfL and GFAP in participants treated with CNM-Au8 Biomarker improvements are strongly associated with longer survival, r...
Clene to Provide CNM-Au8® ALS Program Update
SALT LAKE CITY, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopha...
Clene to Participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference
SALT LAKE CITY, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmace...
Clene Reports Third Quarter 2025 Financial Results and Recent Operating Highlights
As the U.S. Food and Drug Administration (FDA) proposed, Clene is concluding analyses of its ALS biomarker data with completion planned shortly The FDA advised Clene to request a Type C meeting to re...
Clene Transcript: Emerging Growth Conference
Recent FDA engagement has advanced expanded access protocols and highlighted significant survival and biomarker benefits in ALS studies. New data under analysis may enable a new drug application by year-end, with sufficient cash to reach key milestones.
Clene to Participate in a Panel Discussion at the Maxim Growth Summit
SALT LAKE CITY, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmace...
Clene Presents New Clinical Data at ECTRIMS 2025 Meeting Demonstrating CNM-Au8® Improves Brain Energy Metabolism in Multiple Sclerosis Patients
Late-breaking clinical data presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis Across non-active progressive MS (primary progressive and secondar...
Clene Transcript: H.C. Wainwright 27th Annual Global Investment Conference
The conference detailed progress on CNM-Au8 for ALS and MS, highlighting survival and biomarker benefits, a strong safety profile, and ongoing FDA discussions for accelerated approval. Financial resources are sufficient to support regulatory milestones into early next year.
Clene Presents Preclinical Data Supporting CNM-Au8® for the Treatment of Parkinson's Disease
SALT LAKE CITY, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmac...
Clene to Present at the H.C. Wainwright 27th Annual Global Investment Conference
SALT LAKE CITY, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage bioph...
Clene Transcript: Emerging Growth Conference 85
The company is advancing CNM-Au8 for ALS and MS, showing survival and biomarker benefits in clinical trials, with no serious adverse events reported. Key regulatory milestones and data readouts are expected in the coming months, with an NDA filing targeted by year-end.
Clene Reports Second Quarter 2025 Financial Results and Recent Operating Highlights
SALT LAKE CITY, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopha...
Clene Transcript: Canaccord Genuity’s 45th Annual Growth Conference
A nanotherapeutic for ALS is advancing toward potential accelerated FDA approval, with key data on neurofilament and survival endpoints expected in the coming months. The MS program is also progressing, attracting strategic partnering interest. Cash runway extends into Q3, with several regulatory and data catalysts ahead.
Clene to Present at the Canaccord 45th Annual Growth Conference
SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopha...
Clene Transcript: Emerging Growth Conference 84
Recent FDA meetings have set the stage for neurofilament biomarker analysis in ALS, with pivotal data collection and submission planned for Q3–Q4 and a new drug application targeted by year-end. A confirmatory phase III trial will begin late 2024, with global expansion in 2026.
Clene Provides Regulatory Update Following Constructive FDA Type-C Meeting on Neurofilament Biomarker Analysis Plan and Confirms Two Additional FDA Meetings
FDA provides supportive feedback on proposed statistical analysis plan for neurofilament biomarker analysis of Clene's NIH-sponsored Expanded Access Program NfL EAP biomarker analyses to be conducted ...